Reference health
Comparative Effectiveness of SGLT2i Versus DPP4i on Cardiovascular, Kidney and Hyperkalemia Outcomes in Individuals from Routine Clinical Practice: Observational Cohort Study
38/38 checkable references clean · checked 2026-09-06
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
14 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 38 checked references that resolve
resolves10.1016/S0140-6736(16)00618-8
Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants
resolves10.1016/S0140-6736(10)60484-9
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
resolves10.1002/clc.23508
The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now
resolves10.1111/dom.13612
How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study
resolves10.1111/dom.14437
Lower risk of hospitalization for heart failure, kidney disease and death with sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care
resolves10.1161/CIRCULATIONAHA.117.029190
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs
resolves10.1161/CIRCULATIONAHA.118.039177
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care
resolves10.1161/CIRCULATIONAHA.117.031227
Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor
resolves10.1111/dom.13477
Cardiovascular outcomes of sodium glucose cotransporter‐2 inhibitors in patients with type 2 diabetes
resolves10.1111/dom.13424
Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real‐world meta‐analysis of 4 observational databases (OBSERVE‐4D)
resolves10.1016/S2213-8587(17)30258-9
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
resolves10.1016/j.jacc.2018.03.009
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
resolves10.1111/dom.13077
Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (
<scp>CVD‐REAL Nordic</scp>
) when compared with dipeptidyl peptidase‐4 inhibitor therapy:
<scp>A</scp>
multinational observational study
resolves10.1111/dom.12889
Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes
resolves10.2337/dc20-1890
Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases
resolves10.1016/S2213-8587(19)30384-5
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
resolves10.1161/CIRCULATIONAHA.117.032799
Reduced Mortality With Sodium-Glucose Cotransporter–2 Inhibitors in Observational Studies
resolves10.2337/dc17-1223
Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?
resolves10.1161/CIRCULATIONAHA.119.044183
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus
resolves10.1161/STROKEAHA.120.031623
Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease
resolves10.1016/j.jacc.2021.01.044
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure
resolves10.1016/j.jchf.2020.11.009
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists
resolves10.1161/CIRCULATIONAHA.117.028268
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
resolves10.1093/ckj/sfaa133
Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
resolves10.1093/ckj/sfv117
The Stockholm CREAtinine Measurements (SCREAM) project: protocol overview and regional representativeness
resolves10.1093/ckj/sfaa242
Pharmacoepidemiology for nephrologists (part 2): potential biases and how to overcome them
resolves10.1111/dom.12595
Cardiovascular and non‐cardiovascular safety of dipeptidyl peptidase‐4 inhibition: a meta‐analysis of randomized controlled cardiovascular outcome trials
resolves10.1186/1471-2458-11-450
External review and validation of the Swedish national inpatient register
resolves10.7326/0003-4819-150-9-200905050-00006
A New Equation to Estimate Glomerular Filtration Rate
resolves10.1016/S0140-6736(18)32590-X
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
resolves10.1161/CIRCULATIONAHA.120.045864
Preventing Atrial Fibrillation With Treatments for Diabetes Mellitus
resolves10.1016/S2213-8587(19)30422-X
Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map
resolves10.1186/s12933-021-01243-4
SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
resolves10.1136/bmj.b2393
Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls
The 14 references without a DOI — listed, not checked
no DOI — not checkedSodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
no DOI — not checkedref8
no DOI — not checkedAn Analysis of CVD-REAL
no DOI — not checkedCardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
no DOI — not checkedComparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study
no DOI — not checkedUse of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study
no DOI — not checkedUse of sodiumglucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study
no DOI — not checkedSodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
no DOI — not checkedEffects of sodium-glucose co-transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure
no DOI — not checkedref34
no DOI — not checkedref35
no DOI — not checkedref42
no DOI — not checkedref47
no DOI — not checkedThe risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-09-06 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.2139/ssrn.3947641"><img src="https://citestamp.com/citestamped/10.2139/ssrn.3947641/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.2139/ssrn.3947641)